Clinical trial recruitment today identifies who qualifies biologically, but fails to account for whether a person is able, willing, or prepared to participate. Gryt bridges that gap.
CTPA augments diagnosis-based eligibility with lived-experience intelligence to activate, and sustain, real clinical trial participation. Over the past decade, it has successfully enrolled high-priority trials and helped clients achieve FDA goals.
Static inclusion and exclusion criteria identify who qualifies biologically, but ignore whether a patient is able, willing, or prepared to participate. This diagnosis-only approach drives costly enrollment delays, protocol amendments, and early dropouts.
The result: many eligible patients do not enroll, disengage early, or drop out, especially in precision medicine, rare disease, and underrepresented populations. By integrating lived-experience intelligence with clinical eligibility, CTPA enables participation-ready recruitment.
Co-founded by David Craig following experience at Lilly COI and leading LIVESTRONG’s Clinical Trial Matching Service.
Gryt’s first client engagement successfully supported enrollment of Ignyta’s landmark NTRK clinical trial.
Recognized at SCOPE 2019 for industry-leading work in patient engagement and clinical trial participation.
Awarded again at SCOPE 2021, cementing Gryt’s reputation as a leader in participant-centered trial engagement.
Advancing lived-experience intelligence as a core driver of trial success across rare disease, oncology, and underrepresented populations.
Engagement by site location. Each pin is a person who searched, saw the campaign, used Gryt’s engagement platform, and took action toward enrollment.
